OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program

@article{Dodick2010OnabotulinumtoxinAFT,
  title={OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program},
  author={David W. Dodick and Catherine C. Turkel and Ronald E Degryse and Sheena K Aurora and Stephen D. Silberstein and Richard B. Lipton and Hans Christoph Diener and Mitchell F Brin},
  journal={Headache: The Journal of Head and Face Pain},
  year={2010},
  volume={50}
}
(Headache 2010;50:921‐936) 
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program
Objective.— To evaluate safety and efficacy of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine.
A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine
As a post‐approval commitment, this dose‐ranging study was undertaken to evaluate efficacy and safety of onabotulinumtoxinA in adolescents.
Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial
TLDR
This study explored the efficacy of 10mg/d flunarizine for CM prophylaxis as compared with 50 mg/d topiramate.
OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
TLDR
The results from randomized controlled trials often reflect, but rarely define, the spectrum of patient outcomes, and the proportion of patients highly responsive to a therapy is an important endpoint and guide for clinicians and patients.
Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine
To assess the onset of efficacy for fremanezumab in chronic migraine by evaluating pain‐related clinical measures at different time points.
Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial
This study compares efficacy and safety of divalproate extended release (DVA‐ER) and amitriptyline (AMT) in migraine.
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
TLDR
To review the literature on the mechanism of action of onabotulinumtoxinA in chronic migraine, a large number of studies have found it to be a safe and effective treatment for migraine.
Prognosis Following Discontinuation of OnabotulinumA Therapy in “Super‐responding” Chronic Migraine Patients
TLDR
To determine whether the successful treatment of chronic migraine with onabotulinumA (BotoxA) may be followed by a continued respite from headache once therapy has been discontinued, a large number of patients with CM are prescribed Botox.
Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine
TLDR
To determine if chronic migraine patients' improvement in depression is related to improvement in headache severity after onabot injection, a large number of patients with chronic migraine have had a history of depression.
OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
TLDR
This secondary analysis assessed patients who received all five treatment cycles and completed the study to assess efficacy and safety of onabotulinumtoxinA for prophylaxis of headaches in adults with CM.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Objective.—To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.
Botulinum Toxin Type A Prophylactic Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Exploratory Study
Objective.—This exploratory trial evaluated the safety and efficacy of multiple treatments of botulinum toxin type A (BoNTA; BOTOX®, Allergan, Inc., Irvine, CA, USA) as prophylactic treatment of
Placebo response in the prophylaxis of migraine: A meta‐analysis
Background: Migraine constitutes a good model for the study of placebo response. It is a well‐defined disease, affects a large population and a great number of clinical trials have been performed,
Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study
Objective.—To assess the efficacy and safety of botulinum toxin type A (BoNT‐A; BOTOX®, Allergan, Inc., Irvine, CA) for the prophylaxis of headaches in patients with chronic daily headache (CDH)
A Double‐Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study
TLDR
There is a need for effective prophylactic therapy for chronic migraine that has minimal side effects and is safe and effective, and this work contributes towards that goal.
Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled Trial
TLDR
The safety and efficacy of botulinum toxin type A (BoNT‐A; BOTOX®, Allergan, Inc.) for the prophylactic treatment of chronic daily headache is evaluated.
Economic Burden of Transformed Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study
TLDR
The study estimates the total direct and indirect costs associated with transformed migraine and the impact of incident transformed migraine on health care resource utilization, medication use, and productivity loss.
Epidemiology of Chronic Daily Headache in the General Population
TLDR
This study analyzes the prevalence of the different types of chronic daily headache in an unselected population to find out the actual prevalence of transformed migraine.
Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain
Botulinum toxin type A (BTX‐A) has been reported to have analgesic effects independent of its action on muscle tone, possibly by acting on neurogenic inflammation. Such a mechanism may be involved in
Botulinum Toxin Type A in the Treatment of Chronic Migraine Without Medication Overuse
TLDR
This study undertakes to examine the effects of Botulinum Toxin Type A in the absence of medication overuse in patients with chronic migraine.
...
1
2
3
4
5
...